Actively Recruiting
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Led by PharmaEssentia Japan K.K. · Updated on 2024-11-08
67
Participants Needed
6
Research Sites
284 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.
CONDITIONS
Official Title
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who have completed the 52-week treatment duration in Study A19-201 and are considered by the investigator or sub investigator to be eligible for participation in this study
- Patients who have given written informed consent to participate in this study
You will not qualify if you...
- Patients who are considered by the investigator or sub investigator to be ineligible for continued treatment with P1101
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Ehime University Hospital
Toon-shi, Ehime, Japan, 791-0295
Actively Recruiting
2
Mie University Hospital
Tsu, Mie-ken, Japan
Actively Recruiting
3
Osaka University Hospital
Suita-shi, Osaka, Japan, 565-0871
Actively Recruiting
4
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan, 113-8431
Actively Recruiting
5
Tokyo Medical University Hospital
Shinjuku-ku, Tokyo, Japan, 160-0023
Actively Recruiting
6
University of Yamanashi Hospital
Chuo-shi, Yamanashi, Japan, 409-3898
Actively Recruiting
Research Team
H
Hiroaki Kawase
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here